Amylyx Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

Last price 28.86 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.62B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas...